Research

rs17679445 — PNPO Arg116Gln

Missense variant in pyridoxamine 5'-phosphate oxidase that reduces the enzyme's efficiency at converting dietary vitamin B6 into active PLP, the essential cofactor for GABA, serotonin, melatonin, and dopamine synthesis; associated with insomnia risk in large GWAS

Moderate Risk Factor Share

Details

Gene
PNPO
Chromosome
17
Risk allele
A
Clinical
Risk Factor
Evidence
Moderate

Population Frequency

AA
0%
AG
12%
GG
87%

Tags

Sleep Neurotransmitters B Vitamins Melatonin Serotonin Hormones

Category

Hormones & Sleep

External

SNPedia ClinVar dbSNP

See your personal result for PNPO

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PNPO Arg116Gln — When Your Body Can't Activate Vitamin B6

Every neurotransmitter that regulates sleep — serotonin, melatonin, GABA, and dopamine — depends on the same molecular key: pyridoxal 5'-phosphate (PLP), the active form of vitamin B6. Dietary vitamin B6 (pyridoxine or pyridoxamine from food and most supplements) is not active on its own. Before your brain can use it, the enzyme PNPO11 PNPO
Pyridoxamine 5'-phosphate oxidase — catalyzes the final oxidation step converting PNP and PMP to PLP, the biologically active cofactor form of vitamin B6 (pyridoxamine 5'-phosphate oxidase) must convert it to PLP. The rs17679445 Arg116Gln variant substitutes a glutamine for arginine at position 116 of PNPO, reducing the enzyme's catalytic efficiency and thereby limiting the supply of PLP to the neurotransmitter-synthesizing enzymes that depend on it.

The Mechanism

PNPO sits at the final step of B6 activation. It oxidizes both pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP) into PLP. Without adequate PLP, multiple downstream enzymes falter simultaneously. The most sleep-relevant are:

  • Aromatic amino acid decarboxylase (AADC/DDC) — converts 5-HTP to serotonin and L-DOPA to dopamine; requires PLP as essential cofactor. A 2022 structural study22 2022 structural study
    Al Mughram MH et al. Elucidating the Interaction between Pyridoxine 5'-Phosphate Oxidase and Dopa Decarboxylase. Int J Mol Sci, 2022     showed that PNPO physically binds to AADC and directly delivers PLP to it — making PNPO's efficiency a rate-limiting step for serotonin and dopamine production.
  • Glutamic acid decarboxylase (GAD) — converts glutamate to GABA, the brain's primary inhibitory neurotransmitter; PLP-dependent. Reduced GAD activity is the central mechanism in PNPO-deficiency epilepsy.
  • Tryptophan aminotransferase — a PLP-dependent enzyme in the melatonin synthesis pathway. Lower PLP availability reduces pineal melatonin output, as demonstrated in B6-deficient animal models33 B6-deficient animal models
    Dakshinamurti K et al. Neuroendocrinology of pyridoxine deficiency. Neurosci Biobehav Rev, 1988     where B6 deficiency reduced both hypothalamic serotonin and pineal melatonin.

The Arg116Gln substitution replaces a positively charged arginine (which stabilizes the enzyme's active site) with a neutral glutamine. While this does not abolish enzyme function (unlike homozygous loss-of-function mutations that cause neonatal epilepsy), it reduces catalytic efficiency — producing a partial, dose-dependent reduction in PLP output that is particularly relevant in carriers who consume standard (non-activated) vitamin B6 supplements or have modest dietary B6 intake.

The Evidence

The variant's association with insomnia was identified in the landmark Jansen et al. 201944 Jansen et al. 2019
Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nature Genetics, 2019 genome-wide association study of 1,331,010 individuals, which identified 202 insomnia risk loci implicating 956 genes. The PNPO locus on chromosome 17 was among the hits. While GWAS identifies association rather than causation, the biological plausibility is high: the entire neurotransmitter cascade governing sleep initiation and maintenance — serotonin → melatonin, GABA synthesis, dopamine signaling — converges on PLP as a shared cofactor.

A comprehensive 2019 review55 comprehensive 2019 review
Wilson MP et al. Disorders affecting vitamin B6 metabolism. J Inherit Metab Dis, 2019 of vitamin B6 metabolism disorders confirmed that PLP (produced by PNPO) is the sole active cofactor form capable of driving neurotransmitter synthesis reactions in the central nervous system.

Supporting the sleep-B6 link at a clinical level, two controlled trials showed that vitamin B6 supplementation affects sleep architecture. An RCT by Ebben et al. (2002)66 RCT by Ebben et al. (2002)
Ebben M et al. Effects of pyridoxine on dreaming: a preliminary study. Perceptual and Motor Skills, 2002 found that 250 mg pyridoxine before sleep significantly enhanced dream salience (vividness, emotionality, color) compared to placebo over 5 nights, hypothesizing enhanced B6-to-serotonin conversion as the mechanism. A larger RCT by Aspy et al. (2018)77 RCT by Aspy et al. (2018)
Aspy DJ et al. Effects of Vitamin B6 (Pyridoxine) and a B Complex Preparation on Dreaming and Sleep. Perceptual and Motor Skills, 2018 replicated increased dream recall in 100 participants taking 240 mg pyridoxine.

ClinVar classifies the A allele (Arg116Gln) as benign for PNPO-deficiency epilepsy — consistent with the protein retaining substantial function. The sleep association reflects a subtler, quantitative reduction in PLP production relevant at the population level rather than a clinical disease state.

Practical Actions

The key insight for Arg116Gln carriers is the bypass strategy: while standard vitamin B6 supplements contain pyridoxine or pyridoxamine that require PNPO to activate, pyridoxal-5-phosphate (P5P) is the already-activated form that enters cells and reaches neurotransmitter- synthesizing enzymes without needing PNPO conversion. Using P5P directly circumvents the enzymatic bottleneck at the Arg116Gln substitution.

Homozygous A carriers (Arg116Gln/Arg116Gln) represent the extreme of impaired conversion and should particularly consider P5P supplementation. Heterozygous AG carriers have an intermediate phenotype with partial reduction in conversion efficiency.

Interactions

PNPO Arg116Gln is most likely to be clinically relevant in the context of other factors that further stress PLP availability: low dietary B6 intake, high protein intake (which increases B6 demand for amino acid metabolism), oral contraceptive use (which depletes B6), or genetic variants in B6 transport or metabolism. No specific gene-gene interaction studies with rs17679445 have been published, but carriers of both PNPO Arg116Gln and variants affecting tryptophan metabolism (e.g., MTHFR, which shares PLP-dependent enzymes in the one-carbon cycle) may experience compounded effects on neurotransmitter synthesis.

Nutrient Interactions

vitamin B6 impaired_conversion

Genotype Interpretations

What each possible genotype means for this variant:

GG “Standard Converter” Normal

Normal PNPO activity and efficient B6 activation

With the GG genotype, PNPO retains its full arginine at position 116, which contributes to active-site geometry and catalytic efficiency. Your B6 activation pipeline operates without a bottleneck at this enzyme, meaning that standard dietary B6 from foods (poultry, fish, potatoes, bananas) and standard pyridoxine supplements are converted to PLP at a normal rate.

The insomnia-associated Jansen et al. 2019 GWAS identified the PNPO locus as a risk factor, implying that the GG genotype provides a baseline level of protection against this particular PLP-deficiency pathway to insomnia. You are not genetically disadvantaged at this enzymatic step.

AG “Partial Converter” Reduced

One copy of the reduced-activity PNPO allele — modestly lower B6 activation

In the heterozygous state, one PNPO chromosome produces fully functional enzyme (Arg116) while the other produces the reduced-efficiency variant (Gln116). The result is an intermediate level of B6 activation efficiency. While this is not a clinical enzyme deficiency (PNPO homozygous loss-of- function causes neonatal epilepsy), the subtler reduction in PLP output can be meaningful for neurotransmitter synthesis when dietary B6 intake is moderate or when demand is elevated.

The Jansen et al. 2019 insomnia GWAS identified this locus in a dataset of over 1.3 million participants, suggesting the PLP-limitation effect is detectable at the population level. The clearest practical implication is that standard pyridoxine supplements add to the enzymatic burden at the PNPO step — while P5P bypasses it entirely.

AA “Poor Converter” Poor

Two copies of the reduced-activity PNPO allele — substantially impaired B6 activation

As an AA homozygote, both PNPO gene copies carry the Arg116Gln substitution. This is not equivalent to the homozygous null mutations that cause neonatal-onset epileptic encephalopathy (where PNPO function is abolished), but it represents the most impaired PNPO function among common variants. Standard dietary B6 and standard pyridoxine supplements will consistently underperform for this genotype because both forms must pass through PNPO before becoming active.

The downstream consequences center on the neurotransmitter enzymes that require PLP. Aromatic amino acid decarboxylase (serotonin and dopamine synthesis), glutamic acid decarboxylase (GABA), and the tryptophan aminotransferase enzyme in the melatonin pathway all become co-limited by PLP supply. The Jansen et al. 2019 insomnia GWAS finding aligns mechanistically: insufficient serotonin → melatonin conversion and reduced GABAergic signaling are established contributors to insomnia.

Given the rarity of this genotype, direct studies of AA homozygotes in sleep outcomes are not available. The recommendation for P5P supplementation is strongly supported by the mechanistic bypass logic and by evidence from PNPO deficiency literature showing that P5P (but not pyridoxine) normalizes enzyme function downstream.